Research Article

Malignancy Risk Factors of Hydatidiform Mole

Faktor-Faktor Risiko Keganasan pada Molahidatidosa

Akbar N D Saputra[1],Agustria Z Saleh[2],Patiyus Agustiansyah[3],Theodorus[4]

[1,2,3] Department of Obstetrics and Gynaecology
[4]Research Unit of Health and Medicine
Faculty of Medicine Universitas Sriwijaya
Dr. Mohammad Hoesin Hospital
Palembang

Abstract

Objective : to determine risk factors in hydatidiform mole patients who will develop into Gestational Trophoblast Neoplasm (GTN) in Dr. Mohammad Hoesin Hospital Palembang

Methods : An observational analytical study with case-control design was conducted in the Department of Obstetrics and Gynecology in Dr. Mohammad Hoesin Hospital Palembang / Faculty of Medicine Sriwijaya Universitas Palembang from January 2017 to August 2017. The frequency and distribution of data are described in tables. Bivariate analysis was done to determine the correlation between the independent variable and dependent variable using Chi-Square/Fisher Exact test and multivariate analysis was used to know which independent variable has the most significant influence to the occurrence of Gestational Trophoblast Neoplasm (GTN) post-evacuation of hydatidiform mole. Data analysis was done using SPSS version 21.0.

Results : 45 patients fulfilled inclusion criteria with a control group and case group ratio 1 : 2 (15 cases and 30 controls). Statistical analysis showed a significant correlation between patient age, preevacuation β HCG level, parity, and histopathologic appearance with the occurrence of Gestational Trophoblast Neoplasm (GTN) after the evacuation of hydatidiform mole (p <0,05). From multivariate analysis, it was found that pre-evacuation β HCG levels ≥ 134,182.5 mIU/ml were a risk factor of Gestational Trophoblast Neoplasm (OR = 77.008, p-value = 0.004).

Conclusions : Preevacuation β HCG levels ≥ 134,182.5 mIU / ml isa risk factor for the occurrence of Gestational Trophoblast Neoplasm (GTN).

Keywords : age, blood type, hydatidiform mole, histopathology feature, GTN, preevacuation β HCG level, parity, uterine size.

Abstrak

Tujuan : *Untuk mengetahui faktor-faktor risiko pada pasien–pasien molahidatidosa yang akan berkembang menjadi Tumor Trofoblas Gestasional (TTG) di Rumah Sakit Dr. Mohammad Hoesin Palembang*

Metode : *Penelitian analitik observasional dengan studi case control ini dilakukan di Departemen Obstetrik dan Ginekologi RSUP Dr. Mohammad Hoesin Palembang/ Fakultas Kedokteran Universitas Sriwijaya Palembang sejak bulan Januari 2017 sampai Agustus 2017. Frekuensi dan distribusi data dijelaskan dalam bentuk tabel, analisis bivariat untuk mengetahui ada tidaknya hubungan secara statistik antara variabel bebas dengan variabel terikat menggunakan ujiChi Square/ Fisher Exact dan analisis multivariate untuk mengetahui variabel independen mana yang paling besar pengaruhnya terhadap kejadian Tumor Trofoblas Gestasional (TTG) pascaevakuasi molahidatidosa. Analisis data menggunakan SPSS versi 21.0.*

Hasil : *Didapatkan sampel sebanyak 45 pasien yang memenuhi kriteria inklusi. Dengan perbandingan kasus banding kontrol yaitu 1:2; sehingga didapatkan 15 pasien sebagai kasus dan 30 pasien sebagai kontrol. Dengan analisis statistika didapatkan hasil terdapat hubungan yang signifikan antara usia pasien, kadar β HCG praevakuasi, paritas dangan gambaran histopatologi dengan kejadian Tumor Trofoblas Gestasional (TTG) pascaevakuasi molahidatidosa (p< 0,05). Denganan alisis multivariate didapatkan kadar β HCG praevakuasi dengan nilai ≥ 134.182,5 mIU/ml merupakan faktor risiko Tumor Trofoblas Gestasional (OR = 77,008, p value = 0,004).*

Kesimpulan : *Kadar β HCG praevakuasi dengan nilai ≥ 134.182,5 mIU/ml merupakan faktor risiko kejadian Tumor Trofoblas Gestasional (TTG).*

Kata kunci : *gambaran histopatologi, golongan darah, kadar β HCG praevakuasi, molahidatidosa, paritas, TTG, ukuran uterus, usia.*

Correspondence : Akbar N D Saputra. anovan1986@gmail.com

INTRODUCTION

Hydatidiform mole is the most common form of gestational trophoblastic disease (GTD). Hydatidiform mole is an abnormal pregnancy in which some or all chorionicvillus degenerate into grape-like vesicles.[1] Hydatidiform moles may be malignant or benign. The frequency of hydatidiform mole is generally higher in Asian women (1 in every 120 pregnancies) than in Western women (1 in every 2,000 pregnancies).[2] In Indonesia, hydatidiform moles are considered an important disease with high incidence (data at in hospitals in Indonesia, 1 per 40), multiple risk factors, uniform distribution and most of the data is still hospital-based.[3]

Several theories have been proposed to explain the pathogenesis of hydatidiform mole. According to a theory by Hertig and Mansell, the cause of hydatidiform mole is an inadequacy of fetal blood circulation. Trophoblast cells receive nutrition from the mother through the intervillous chamber then send the liquid to the villi. Due to the dysfunctional villous blood circulation, fluid accumulates in villous mesenchymal tissue and forms small cysts. This continues and will eventually result in hydatidiform mole.[4,5]

Patient with normal pregnancy who has previous history of hydatidiform mole is considered healthy, and hence, follow-up supervision is no longer necessary. If malignancy occurs, it is not caused by the former hydatidiform mole, but as a result of the last labour. A theory states a number of trophoblast cells in hydatidiform mole sometimes appear quiet (dormant cells) for some time and the existence of pregnancy (the influence of estrogen) reactivates these cells. In this case, the choriocarcinoma arises not from the last pregnancy, but the previous mole.[4,5]

Malignancy following evacuation of hydatidiform mole occurs in 15-20%. Post-mole malignancy develops very rapidly with a high mortality number of 31-51 %.[6,7] The risk of malignancy after the evacuation of the mole is not clearly known. Several demographic, clinical and laboratory variables have been studied as malignant risk factors such as age, parity, uterine size, lutein cyst, histopathological features and also pre-evacuation β-human chorionic gonadotropin (β-HCG) level.[8-10]

This study aimed to determine risk factors of the occurrence of Gestational Trophoblast Neoplasm (GTN) following hydatidiform mole evacuation, so it can be used to predict whether hydatidiform mole will develop into GTN (Gestational Trophoblastic Neoplasm) or return to normal.

METHOD

This observational analytic study with case-control (retrospective) design was conducted in the Department of Obstetrics and Gynecology in Dr. Mohammad Hoesin hospital Palembang/ Faculty of Medicine Universitas Sriwijaya Palembang from January to August 2017. Data was collected by gathering medical record data of hydatidiform mole patients who came and were treated in the Department of Obstetrics and Gynecology in Dr. Mohammad Hoesin hospital Palembang from January 1st 2014 to December 31st 2016. Samples were selected using purposive sampling by choosing patient who met the research criteria. The sample was then divided into 2 groups, with 1:2 proportion between the case group and the control group. The control group was the hydatidiform mole group that had regressed, and the case group was the hydatidiform mole group that developed into GTN. Independent variables were age, pre-evacuated HCG levels, blood type, parity, uterine size, histopathologic features.

Univariate analysis was performed on sample demographic characteristics. Bivariate analyses using chi-square or Fisher exact test were performed to assess the association between age, pre-evacuation HCG levels, blood type, parity, uterine size, histopathologic features and malignancy occurrences in hydatidiform mole. Logistic regression analysis was performed to determine which independent variables had the greatest effect on the occurrence of GTN after hydatidiform mole evacuation.

RESULT

There were 45 hydatidiform mole patients who met the inclusion criteria. Of the 45 patients with hydatidiform mole, 15 patients developed Gestational Trophoblast Neoplasm, and 30 patients regressed.Of 45 patients,30 regressed patients(66,7%) have mean age 27,37 ± 7,63 (age range 17-45 years old) and 15 patients

who developed into GTN(33.3%) have mean age 35.13 ± 10.01 (age range 17-50 years old). Based on statistical analysis, there was a significant difference in age between regressed patients and GTN patients (p = 0.006).

The mean of pre-evacuation β HCG level in the regressed group was 69617,6 ± 38449,7 mIU/ml and the mean of pre-evacuation β HCG level in the GTN group was 515286,4 ± 346728,0 mIU/ml. From statistical analysis, it was found that there was a significant difference in pre-evacuation HCG levels between the two groups (p = 0,000). No significant difference was observed in both groups for other demographic and clinical characteristics (p> 0.05) as shown in Table 1.

Table 1. Characteristics of Subjects

Characteristics	Hydatidiform Mole		*P-value*
	GTN	Non-GTN	
Age (years), mean ± SD	35.13 ± 10.01	27.37 ± 7.63	0.006*
Education, (n,%)			
Elementary	0 (0)	2 (6,7)	
Junior High School	3 (20)	3 (10)	0.496**
Senior High School	10 (66,7)	23 (76.7)	
College	2 (13.3)	2 (6.7)	
Occupation, (n,%)			
Housewife	11 (73.3)	25 (83.3)	
Farmer	0 (0)	3 (10)	0.106**
University student	0 (0)	1 (3.3)	
Employee	2 (13.3)	1 (3.3)	
Civil servant	2 (13.3)	0 (0)	
Pre-evacuation β HCG Levels, mean ± SD	515286.4 ± 346728.0	69617.6 ± 38449.7	0.000***
Blood Group			
A	6 (40)	10 (33.3)	0.470**
B	7 (46.7)	11 (36.7)	
O	2 (13.3)	9 (30)	
AB	0 (0)	0 (0)	
Uterine size			
Bigger	15(100)	29 (96.7)	1.000****
Smaller/appropiate	0 (0)	1 (3.3)	

*Independent T Test, p = 0,05 , **Pearson Chi Square, p = 0,05, ***Mann Whitney test, p = 0,05
*****Fisher Exact test, p=0,05

ROC curve analysis was performed to obtain the cut-off point with the best sensitivity and specificity values for age, parity and preevacuation β HCG level. Based on the ROC curve, the cut-off point was 29.5 years for age, the best parity at 1.5 and the best preevacuation β HCG level at 134.182,5 mIU / ml. Analysis results from ROC curve for age, parity and β HCG is used to analyse the relationship between the independent variables and the occurrence of Gestational Trophoblast Neoplasm (GTN) in hydatidiform mole patients.

In GTN patients the majority (73.3%) of patients was ≥ 29.5 years old whereas in non-GTN patients the majority (66.7%)was<29.5 years old. For parity variables, in GTN patients the majority of patients had a parity of ≥ 1.5 (66.6%) whereas the majority non-GTN patients (73.3%) had parity <1.5. Meanwhile, for the predominant β HCG levels, the majority of patients (93.3%) of the GTN had pre-evacuation β HCG ≥ 134.182.5 mIU / ml, whereas the majority non-GTN patients (93.3%) of had pre-treatment β HCG levels <134.182.5 mIU / ml. Table 2 shows that there is a significant association between age, parity, pre-evacuation βHCG levels and histopathology features and gestational trophoblast neoplasm occurrence in hydatidiform mole patients (p <0.05).

Table2. Association between Age, Parity, pre-evacuation β HCG Level, Histopathology Feature and Gestational Trophoblast Neoplasm Occurrence in Hydatidiform Mole Patients

Characteristics	Hydatidiform Mole		Total	OR* (CI 95%)	*P-value*
	GTN	Non-GTN			
Age (years old)					
≥ 29.5	11	10	21	5.500	0.025
< 29.5	4	20	24	(1.393-21.715)	
Parity					
≥ 1.5	10	8	18	5.500	0.024
< 1.5	5	22	27	(1.434-21.096)	
Pre-evacuation β HCG level					
≥ 134.182,5mIU/ml	14	2	16	196.000	0.000
< 134.182,5mIU/ml	1	28	29	(16.337-2351.532)	
Histopathology Feature					
Moderate-severe proliferation	14	6	20	56.000	0.000
Mild Proliferation	1	24	25	(6.099-514.189)	

* Fisher Exact test, p-value = 0.05

Based on the logistic regression test in table 3, it was found that pre-evacuation β HCG level significantly influenced the occurrence of GTN. Risk of progressing to GTN in patients with pre-evacuation β HCG level ≥134.182,5mIU / ml was 77 times greater than in patients with pre-evacuation β HCG levels <134.182,5 mIU/ml (OR = 77.008, P value = 0.004). While age, parity and histopathology feature were significantly associated with β HCG level (OR > 1, p-value <0.05).

Table3. Risk Factors of Gestational Trophoblast Neoplasm

Variable	Unadjusted*		Adjusted**	
	OR	*P- value*	OR	*P- value*
β HCG level	196.000	0.000	77.008	0.004
Histopathology feature	56.000	0.000	7.423	0.227
Parity	5.500	0.024	5.025	0.295
Age	5.500	0.025	0.813	0.890

**Regression logistic test,p-value=0.05

DISCUSSION

Gestational trophoblast disease (GTD) is defined as a neoplastic process, derived from fetal chorion during pregnancy.[11,12] This includes a spectrum of diseases such as molar pregnancy, persistent invasive mole, gestational choriocarcinoma and placental-site trophoblast tumor.[13,14]

Gestational Trophoblast Neoplasm (GTN) is a disease condition where there is clinical evidence of invasive mole or choriocarcinoma. The incidence of gestational trophoblast neoplasm in Indonesia varies between 11.47 - 29.3%.[3] In this study, we obtained 45 patients of hydatidiform moles; 15 (33.3%) of which developed into GTN. The number is relatively higher when compared to the incidence of post-mole GTN in Indonesia in previous studies, which range from 11.47 to 29.3% .[3] This may be due to Dr. Mohammad Hoesin Hospital Palembang status as a tertiary health care facility and a regional referral hospital. Hence, many subspecialists cases that cannot be handled at a local hospital can be found in Dr. Mohammad Hoesin Hospital.

Mean age of GTN patients in this study was 35.13 ± 10.01 (age range 17-50), with statistical analysis showed significant difference between mean age of the non-GNT patient and mean age of patients where mean age in GTN patients was higher. The results of this study are similar to the study by Azis et al who found an increasing incidence of invasive mole and choriocarcinoma in patients over 35-40 years old.[15,16]

Bivariate analysis showed that hydatidiform mole patients age ≥ 29.5 years old were 5.5 times more at risk of progressing to GTN than patients age<29.5 years old. This result is not much different from Soeharyono's research in which patients age ≥ 35 years were 6.6 times more at risk of trophoblastic disease. However, a study conducted by Curry did not show a significant relationship between age andpost-mole malignancy.[13-15]

Majority of patients in this study, both in groups of GTN and non-GTN, have blood type B, followed by blood type A and blood type O. However, no AB blood type was found in both groups. With statistical analysis, there was no difference of blood type groups between the two groups. A research by Soeharyono (1996) showed that most malignancy cases occurred in blood type O patients, then blood type B, blood type A, and blood type AB. This difference is probably due to the smaller number of samples in this study compared to Soeharyono's study (321 samples), so the possibility of finding blood type O is higher. [13,16]In the study by Aziz et al, patients with blood type O and B were found to be more likely to develop malignancy than patients with other blood types.[13] While in the research conducted by Martaadisubrata in 2005, it was found that 33.3% of blood type A patients developed into choriocarcinoma.[1] The results of Bagshawe's study found that blood type A had a higher risk for choriocarcinoma when the blood type of the husband was O.[17]

The association between parity (gravidity) and post-mole malignancy is still unclear. Some studies have found that the risk of malignancy was higher in higher parity, while other authors did not find a relationship between parity and the risk of post-mole malignancy. [13,16] In this study, we found that hydatidiform mole patients with parity ≥ 1.5 were 5.5 times more at risk of progressing to GTN than patients with parity<1.5. Statistical analysis showed a significant association.

Curry found that patients with larger uterine size and an enlarged ovary have higher risk of post-mole malignancy. However, in this study, no difference in uterine size was found between the two groups. All GTN patients had larger uterine size than gestational age, and only one non-GTN patient had a uterine size in accordance with gestational age.[15,16,18]

The serum concentration of β HCG is recognised as an important prognostic indicator of gestational trophoblastic disease. According to FIGO, postevacuation treatment of hydatidiform mole involves examining β-HCG every week during the first month until undetectable. The β-HCG level in most cases will return to normal within eight weeks, and the others will return to normal within 14-16 weeks after evacuation. Meanwhile, according to Berkowitz and Goldstein, β-HCG levels in hydatidiform mole patients usually will return to normal within 9-11 weeks after evacuation. However, if, during the follow-up, there is an elevated β-HCG level or plateau then the diagnosis of GTN can be established.[13,19,20]

In this study, the mean pre-evacuation β HCG level was 515286,4 ± 346728,0 mIu/ml. Then the preevacuation β HCG level was divided into ≥134.182,5mIU/ml and <134.182,5 mIU/ml based on analysis results with ROC curve. With bivariate analysis, we found that hydatidiform mole patients with preevacuation β HCG level ≥134.182.5 mIU/ml were significantly more at risk (196 times more at risk)of progressing to GTN than patients with pre-evacuation β HCG level <134.182,5 mIU/ml. This result is similar to the study by Goldstein and Berkowitz which concluded that high pre-evacuation β HCGtiter above 100,000 SI / l was a high-risk factor for malignancy. [14,15,17]

In this study, we found that hydatidiform mole patients with moderate-to-severe proliferation from histopathology feature were significantly more at risk (56 times higher) of progressing to GTN than patients with mild proliferation. This result is consistent with the study by Hertig and Sheldon, which found an association between the severity of trophoblastic hyperplasia in hydatidiform mole and the onset of malignancy. The more severe the hyperplasia and anaplasia found in histopathologic examinations, the more likely it is to become malignant. Based on the severity of hyperplasia and trophoblast cell anaplasia, a histologic hydatidiform mole classification was formulated in 1956 and was simplified by Hertig and Mansel.[17]

Based on multivariate analysis, the risk factor for the occurrence of gestational trophoblast neoplasm was preevacuation β HCG level ≥ 134.182,5 mIU/ml while other variables were not risked factors because no statistically significant correlation was found. The results were slightly different from the studies by Lurain JR and Loh KY et al. They reported that the risk factors for post hydatidiform mole malignancy were histopathologic features with severe proliferation, uterine size, lutein cysts> 6 cm and pre-evacuation β-HCG levels> 100,000 mIU / mL.[8- 10]

CONCLUSIONS

Pre-evacuation β HCG levels ≥ 134,182.5 mIU/ml is a risk factor for the occurrence of GTN.

SUGGESTION

Follow-up studies with prospective cohort designs and large sample, which incorporate other risk factors should be conducted to provide more valid and targeted results and conclusions.

REFFERENCES

1. Martaadisoebrata D. Molahidatidosa dalam Buku Pedoman Pengelolaan Penyakit Trofoblas Gestasional. Jakarta: EGC; 2005: 7–41.
2. Andrijono A. Deteksi Dini Penyakit Trofoblas Ganas dalam Deteksi Dini Penyakit Kanker. Jakarta : FKUI ; 2004: 130–3.
3. Pradjatmo H, Dasuki D, Dwianingsih EK, Triningsih E. Malignancy risk scoring of hydatidiform moles. Asian Pacific J Cancer Prev, 2015; 16:2441-5.
4. Khrismawan, Saleh AZ, Sanif R, Theodorus. Ketepatan Prediksi Penyakit Trofoblas Ganas dengan Menggunakan Skoring Faktor Risiko pada Molahidatidosa. Palembang; Tesis Fakultas Kedokteran Unsri. 2003.
5. Paradinas FJ, Hancock BW, Newland ES, Berkowitz RS. Gestational trophoblastic disease. 1st ed. London : Chapman & Hall Medical; 1997:44-76.
6. Soper JT. Gestational trophoblastic disease. Am College Obstet Gynecol. 2006;108(1): 176-87.
7. Seckl MJ, Sebire MJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717-29.
8. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.
9. Deep JP, Sedhai LB, Napit J, Pariyar J. Gestasional trophoblastic disease. J Chitwan Med College. 2013;3(4):4-11.
10. Loh KY, Sivalingam N, Suryani MY. Gestational trophoblastic disease. Med J Malay. 2004;59(5):697–703.
11. Prawirohadrjo S. Molahidatidosa dalam Ilmu Kandungan, Ed kedua, Cet ketiga. Jakarta:Yayasan Bina Pustaka Sarwono Prawirohardjo; 1999: 114-27.
12. Kamariah K, Satgunasingan N, Nasri NMI, Ng KY. Hydatidiform mole and post-evacuation regression patterns. of serum beta human chorionic gonadotrophin. Med J Malay, 1993;48(1): 40-5.
13. Aziz MF, Kompono N, Samil RS. Neoplasma trofoblas, faktor risiko tinggi dan prognosis. Dalam Aziz FF. (editor) Neoplasma Trofoblas Gestasional. Jakarta: Penerbit Bagian Obstetri dan Ginekologi FKUI ;1995:35-54.
14. Martaadisoebrata D, Sumapraja, S. Penyakit Serta Kelainan Plasenta dan Selaput Janin Ilmu Kebidanan. Jakarta :Yayasan Bina Pustaka Sarwono Prawirohardjo.2002:341-8.
15. Hurteau JA. Gestational trophoblastic disease: Management of hydatidiform mole. Clin Obstet Gynecol. 2003;3:557-69.
16. Szulman AE, Surti U. The syndromes of hydatidiform mole: I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978;131:665.
17. Berkowitz RS, Goldstein DP. Gestationaltrophoblastic disease. In: Berek GS, Adashi EY, Hillard PA. Novaks gynecology. 12 th ed. Baltimore: Williams & Wilkins; 1996: 1261-82.
18. Mose JC. Assessment of choriocarcinoma and gestational trophoblastic disease by color Doppler ultrasound. Dalam: Kumpulan makalah seminar ultrasonografionkologi. Bandung:Bagian/ SMF Obstetri&Ginekologi FKUP/RSHS ;1999: 1-5.
19. FIGO. Special report on gynecologic cancer 2000. Int J Gynecol Oncol. 2000: 70; 249-53.
20. Aziz MF, Kampono N, Moegni EM, Sjamsudin S, Barnas B, Samil RS. Epidemiology of gestational trophoblastic neoplasm at the Dr.Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Adv Exp Med Biol 1984;176:165-75.